Serina Therapeutics, Inc. — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/107d1f97-ec7a-4887-b6ae-2cfc1db6e000/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $130.0k | 2025-01-01 – 2025-12-31 | evidence 0001708599-26-000016 |
| FY 2024 | $56.0k | 2024-01-01 – 2024-12-31 | evidence 0001708599-25-000027 |
| FY 2023 | $3.2M | 2023-01-01 – 2023-12-31 | evidence 0001708599-25-000027 |
| FY 2022 | $34.0k | 2022-01-01 – 2022-12-31 | evidence 0001493152-23-010285 |
| FY 2021 | $144.0k | 2021-01-01 – 2021-12-31 | evidence 0001493152-22-008028 |
| FY 2020 | $361.0k | 2020-01-01 – 2020-12-31 | evidence 0001493152-22-008028 |
| FY 2019 | $1.7M | 2019-01-01 – 2019-12-31 | evidence 0001493152-20-005509 |
| FY 2018 | $1.4M | 2018-01-01 – 2018-12-31 | evidence 0001493152-19-004614 |
| FY 2017 | $1.4M | 2017-01-01 – 2017-12-31 | evidence 0001493152-19-004614 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Serina Therapeutics, Inc. — all facts · Net Income · Operating Income